By SPC News Staff
The FDA granted a new indication for atezolizumab (Tecentriq, Genentech) plus chemotherapy for the treatment of adults with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) in people whose tumors express programmed death ligand-1 (PD-L1), as determined by an FDA-approved test.
This indication is approved under an accelerated approval based on progression-free survival (PFS).
In TNBC, tumor cells lack hormone receptors and do not have excess